Madrigal Pharmaceuticals, Inc. MDGL EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s EPS (basic)?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported EPS (basic) of -$3.25 in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s EPS (basic) changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s EPS (basic) decreased by 24.5% year-over-year, from -$2.61 to -$3.25.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s EPS (basic)?
- Over 3 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s EPS (basic) has grown at a -11.4% compound annual growth rate (CAGR), from -$14.61 to -$10.15.
- What does EPS (basic) mean?
- The portion of a company's profit allocated to each outstanding share of common stock.
- How do you interpret EPS (basic)?
- Higher values indicate greater profitability per share, while negative values reflect a net loss per share.
- How does EPS (basic) compare across companies?
- Commonly compared across the pharmaceutical sector to assess valuation multiples like the price-to-earnings ratio.